On 30 September 2026, the CSRC issued supplementary filing requirements to five companies pursuing Hong Kong listings, covering capital and compliance.
On 30 September 2026, AMLOGIC (688099.SH) completed CSRC filing for up to 53,815,500 shares to be listed on HKEX, under a notice dated 24 August 2026.
On 30 September 2026, TGOOD (300001.SZ) said it received a CSRC filing notice for an H-share offering of up to 134,847,300 shares to be listed on HKEX.
On 29 September 2026, YUDO filed for an HKEX Main Board listing with CICC and CITIC Securities as joint sponsors. It is the world's largest HRS provider.
On 30 September 2026, CSPC PHARMA reported positive Phase III results for its GLP-1 receptor agonist Efmedaglutide Alfa Injection in type 2 diabetes.
On 30 September 2026, CHINA LONGYUAN (00916.HK) said it issued two 210-day ultra-short-term note tranches at a 1.35% coupon, raising RMB 3bn in total.
On September 30, 2026, the Hong Kong ETF market was dominated by biotech and healthcare themes. ChinaAMC Hang Seng Biotech ETF (3069.HK) led with a 4.01% gain; Global X China Biotech ETF, CSOP Hang Seng Biotech ETF and ChinaAMC Innovative Drugs all rose more than 3.2%, and six of the top ten gainers were biotech- or healthcare-related products. Japanese themes strengthened in tandem, and baijiu also performed. On the downside, STAR 50 themes pulled back, with Bosera STAR 50 Index ETF (2832.HK) falling 2.61% to lead the declines, while resources and technology themes weakened modestly. Among Southbound (Stock Connect) ETFs, biotech products led the gains, three products closed flat, and only two posted small declines.
On September 30, 2026, CAMSENSE rose 265.68% to top the gainers; Z.AI led liquidity with turnover of HKD 2.711 billion; TONGSHIFU and HUAYAN ROBOTICS saw their lock-ups released today.
On September 30, 2026, the three major Hong Kong indices closed higher: the Hang Seng Index rose 0.37%, the Hang Seng TECH Index gained 0.10% and the Hang Seng China Enterprises Index rose 0.50%. HSI full-day turnover was HKD 187.2 billion, up from the previous trading day.
On 30 September 2026, MEIG (03268.HK) said its Shanghai joint venture Meige Guangxin has completed industrial and commercial registration with RMB 100m capital.
On 30 September 2026, INSILICO (03696.HK) named ISM1354 a potentially best-in-class GIPR antagonist as preclinical candidate for obesity and type 2 diabetes.
On September 30, 2026, XPENG-W (09868.HK) edged higher. As of 14:06, it traded at HK$37.74, up 0.64%.
E Fund (HK) CSI Liquor Index ETF (03189.HK) fell 25.62% YTD, beating the CSI Liquor Index; baijiu stocks rebounded on 30 September and it closed at HKD 1.078.
As of 10:53 HKT on Sept 30, 2026, CSOP Hang Seng HK-US TECH ETF (03442.HK) fell 0.06% to HK$7.745, tracking the Hang Seng HK-US TECH Index, HK$689m in assets.
As of 10:51 HKT on Sept 30, 2026, Ping An of China CSI HK Dividend ETF (03070.HK) rose 0.34% to HK$41.680, with HK$1.37bn in assets and a 4.73% yield.
As of 10:33 HKT on Sept 30, 2026, CSOP MSCI HK China Connect Select ETF (03432.HK) rose 1.19% to HK$106.150, tracking the MSCI HK China Connect Select Index.
